用PBPK模型预测利福平与利托那韦增效阿扎那韦的药物相互作用
本研究利用PBPK模型模拟利福平(RIF)与利托那韦增效阿扎那韦(ATV/r)的相互作用,模型经临床数据验证(预测值与观测值在2倍内)。模拟显示将ATV/r改为每日两次(300/100或300/200 mg)可使>95%个体ATV谷浓度高于150 ng/mL临床界值,减轻RIF的诱导效应。
要点
- PBPK模型可准确预测RIF对ATV/r的诱导型相互作用。
- 改为每日两次ATV/r 300/100或300/200 mg可能克服RIF诱导。
- 模拟预测>95%个体ATV谷浓度可维持在150 ng/mL以上。
核心结论
- PBPK模型成功表征RIF与ATV/r的诱导介导DDI,预测ATV浓度下降与临床数据一致。
- 将ATV/r从每日一次改为每日两次可减轻DDI对ATV谷浓度的影响,使多数患者浓度高于治疗阈值。
研究设计与样本
- 研究采用全身PBPK模型(Simbiology 9.6.0,MATLAB R2019a),针对单用及联用药物对照已发表临床数据进行验证。
- 模型纳入RIF和利托那韦的诱导机制、利托那韦对相关酶的抑制效应,以及两者对肝脏摄取和外排转运体的诱导与抑制机制。
- 验证标准为观测值与预测值均在2倍以内。
主要发现
- PBPK模型按2倍标准成功验证。
- 模拟不同剂量调整预测,改为每日两次ATV/r(300/100或300/200 mg)可减轻RIF对ATV谷浓度的诱导效应。
- 预测>95%的个体ATV谷浓度高于150 ng/mL临床界值。
关键数值与推荐
- 模型验证标准:观测值与预测值在2倍以内。
- 模拟目标:ATV谷浓度(Ctrough)临床界值为150 ng/mL。
- 推荐模拟方案:ATV/r每日两次300/100 mg或300/200 mg,预测>95%个体Ctrough高于150 ng/mL。
临床怎么用
- 对于HIV合并结核病患者,使用RIF时可将ATV/r调整为每日两次300/100或300/200 mg以维持ATV谷浓度。
- 临床决策可参考PBPK模型预测结果,但需结合患者个体情况与治疗药物监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to simulate the drug-drug interaction (DDI) between ritonavir-boosted atazanavir (ATV/r) and rifampicin (RIF) using physiologically based pharmacokinetic (PBPK) modelling, and to predict suitable dose adjustments for ATV/r for the treatment of people living with HIV (PLWH) co-infected with tuberculosis. METHODS: A whole-body DDI PBPK model was designed using Simbiology 9.6.0 (MATLAB R2019a) and verified against reported clinical data for all drugs administered alone and concomitantly. The model contained the induction mechanisms of RIF and ritonavir (RTV), the inhibition effect of RTV for the enzymes involved in the DDI, and the induction and inhibition mechanisms of RIF and RTV on the uptake and efflux hepatic transporters. The model was considered verified if the observed versus predicted pharmacokinetic values were within twofold. Alternative ATV/r dosing regimens were simulated to achieve the trough concentration (Ctrough) clinical cut-off of 150 ng/mL. RESULTS: The PBPK model was successfully verified according to the criteria. Simulation of different dose adjustments predicted that a change in regimen to twice-daily ATV/r (300/100 or 300/200 mg) may alleviate the induction effect of RIF on ATV Ctrough, with > 95% of individuals predicted to achieve Ctrough above the clinical cut-off. CONCLUSIONS: The developed PBPK model characterized the induction-mediated DDI between RIF and ATV/r, accurately predicting the reduction of ATV plasma concentrations in line with observed clinical data. A change in the ATV/r dosing regimen from once-daily to twice-daily was predicted to mitigate the effect of the DDI on the Ctrough of ATV, maintaining plasma concentration levels above the therapeutic threshold for most patients.
引用
- Montanha MC, Fabrega F, Howarth A, et al. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clin Pharmacokinet. 2021. PMID: 34635995. doi:10.1007/s40262-021-01067-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。